Yilmaz Senay, Demirci Nilgun Yilmaz, Metintas Selma, Zamani Adil, Karadag Mehmet, Guçlu Ozge A, Kabalak Pinar Akin, Yilmaz Ulku, Ak Guntulu, Kizilgoz Derya, Ozturk Akin, Yilmaz Ufuk, Batum Ozgur, Kavas Murat, Serifoglu Irem, Unsal Meftun, Komurcuoglu Berna E, Cengiz Tuba Inal, Ulubay Gaye, Ozdemirel Tugce S, Ozyurek Berna A, Kavurgaci Suna, Alizoroglu Dursun, Celik Pinar, Erdogan Yurdanur, In Erdal, Aksoy Asude, Altin Sedat, Gunluoglu Gulsah, Metintas Muzaffer
Department of Chest Disease, Eskisehir Osmangazi University Medical Faculty (Dr Yilmaz); Department of Chest Diseases, Gazi University Medical Faculty (Dr Demirci); Lung and Pleural Cancers Research and Clinical Center, Eskisehir Osmangazi University (Dr Metintas, Dr Ak, Dr Metintas), Eskisehir; Department of Chest Diseases, Necmettin Erbakan University Meram Medical Faculty, Konya (Dr Zamani); Department of Chest Diseases, Uludag University Medical Faculty, Bursa (Dr Guçlu, Dr Karadag); Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Health Science University (Dr Kabalak, Dr Yilmaz, Dr Kizilgoz, Dr Cengiz, Dr Ozdemirel, Dr Ozyurek, Dr Kavurgaci, Dr Erdogan); Sureyyapasa Chest Disease and Thoracic Surgery Training and Research Hospital (Dr Ozturk, Dr Kavas); Izmir Dr. Suat Seren Chest Diseases and Thoracic Surgery Training and Research Hospital, Health Science University, Izmir (Dr Yilmaz, Dr Batum, Dr Komurcuoglu, Dr Alizoroglu); Department of Chest Diseases, Baskent University Medical Faculty (Dr Serifoglu, Dr Ulubay), Ankara; Department of Chest Diseases, Ondokuz Mayis University Medical Faculty, Samsun (Dr Unsal); Department of Chest Diseases, Celal Bayar University Medical Faculty, Manisa (Dr Celik); Department of Chest Diseases (Dr In); Department of Medical Oncology (Dr Aksoy), Firat University Medical Faculty, Elaziğ; Yedikule Chest Diseases and Chest Surgery Hospital (Dr Altin, Dr Gunluoglu), Health Science University, Istanbul, Turkey.
J Occup Environ Med. 2021 Mar 1;63(3):238-243. doi: 10.1097/JOM.0000000000002115.
The aim of this study is to investigate the effect of asbestos exposure on cancer-driver mutations.
Between January 2014 and September 2018, epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase (ALK), and c-ros oncogene 1 receptor tyrosine kinase gene (ROS1) alterations, demographic characteristics, asbestos exposure, and asbestos-related radiological findings of 1904 patients with lung adenocarcinoma were recorded.
The frequencies of EGFR mutations, ALK, and ROS1 rearrangements were 14.5%, 3.7%, and 0.9%, respectively. The rates of EGFR mutations and ALK rearrangements were more frequent in asbestos exposed non-smokers (48.7% and 9%, respectively). EGFR mutation rate was correlated to female gender and not-smoking, ALK rearrangement rate was correlated to younger age, not-smoking, and a history of asbestos exposure.
The higher rate of ALK rearrangements in asbestos-exposed lung adenocarcinoma cases shows that asbestos exposure may most likely cause genetic alterations that drive pulmonary adenocarcinogenesis.
本研究旨在调查石棉暴露对癌症驱动基因突变的影响。
记录2014年1月至2018年9月期间1904例肺腺癌患者的表皮生长因子受体（EGFR）、间变性淋巴瘤受体酪氨酸激酶（ALK）和c-ros癌基因1受体酪氨酸激酶基因（ROS1）改变、人口统计学特征、石棉暴露情况以及石棉相关的影像学检查结果。
EGFR突变、ALK和ROS1重排的频率分别为14.5%、3.7%和0.9%。在石棉暴露的非吸烟者中，EGFR突变率和ALK重排率更高（分别为48.7%和9%）。EGFR突变率与女性性别和不吸烟相关，ALK重排率与年轻、不吸烟以及石棉暴露史相关。
石棉暴露的肺腺癌病例中ALK重排率较高，表明石棉暴露很可能会导致驱动肺腺癌发生的基因改变。
